{"id":"pyricarbate","rwe":[{"pmid":"6506010","year":"1984","title":"[Acute hepatitis due to pyricarbate (Angioxine). Apropos of 5 cases].","finding":"","journal":"Therapie","studyType":"Clinical Study"},{"pmid":"6745580","year":"1984","title":"[Hepatitis from pyricarbate].","finding":"","journal":"Gastroenterologie clinique et biologique","studyType":"Clinical Study"}],"tags":[{"label":"pyricarbate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Explosive Agents","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"anginin","offLabel":[],"synonyms":["pyricarbate","anginin","anginine","angioxine","pyridinol carbamate","prodectin"],"timeline":[],"approvals":[],"brandName":"Anginin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"pyricarbate","explanation":"Imagine your body's cells have a complex communication system. Anginin is believed to interact with this system, influencing how cells respond to certain signals. This interaction may help to regulate various cellular processes, but more research is needed to fully understand how it works.","oneSentence":"Anginin (PYRICARBATE) is thought to work by modulating a specific biological pathway, although the exact mechanism is not well understood.","technicalDetail":"As a pyricarbate, Anginin likely exerts its effects through a specific interaction with a biological target, potentially influencing enzyme activity or receptor binding. However, the precise molecular details of its mechanism remain unclear."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2329","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PYRICARBATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PYRICARBATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:28:22.043823","biosimilars":[],"competitors":[],"genericName":"pyricarbate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06579222","phase":"NA","title":"Comorbidity Management in Rheumatic Disease.","status":"RECRUITING","sponsor":"Western University, Canada","startDate":"2025-05-01","conditions":["Rheumatoid Arthritis","Comorbidities and Coexisting Conditions"],"enrollment":199,"completionDate":"2026-12-19"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166706","NDDF":"007074","UNII":"81R511UV73","CHEBI":"CHEBI:32075","INN_ID":"5011","RXNORM":"8997","UMLSCUI":"C0034257","ChEMBL_ID":"CHEMBL1620144","KEGG_DRUG":"D01396","PUBCHEM_CID":"4990","MESH_DESCRIPTOR_UI":"D011727"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1984 Sep-Oct","pmid":"6506010","title":"[Acute hepatitis due to pyricarbate (Angioxine). Apropos of 5 cases].","journal":"Therapie"},{"date":"1984 Jun-Jul","pmid":"6745580","title":"[Hepatitis from pyricarbate].","journal":"Gastroenterologie clinique et biologique"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anginin (PYRICARBATE) is a small molecule drug in the pyricarbate class, but details about its development, approval status, and commercial availability are not available. As a result, there is limited information about its target, approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the clinical applications and safety profile of Anginin. The commercial status of Anginin is also unclear, making it difficult to determine if it is patented or available as a generic product. Overall, Anginin remains a relatively unknown compound in the pharmaceutical industry.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}